Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P148 | DOI: 10.1530/endoabs.63.P148

ECE2019 Poster Presentations Diabetes, Obesity and Metabolism 1 (104 abstracts)

Prevalence and risk factors of hepatic steatosis among patients with chronic hepatitis B

Myriam Ayari , Hella Kchir , Dhouha Cherif , Dhilel Issaoui & Nadia Maamouri


La Rabta Hospital, Tunis, Tunisia.


Introduction: Chronic hepatitis and NAFLD represent a global public health problem since they are two common cause of chronic liver disease. Hepatic steatosis (HS) is becoming highly prevalent worldwide and its association with hepatitis B, although controversial previously, is increasingly encountered and thought to be related to host factors.

Aim and methods: The aim of this retrospective study is to determine the prevalence of HS in chronic hepatitis B (CHB) patients and to investigate causes of fatty liver. This study included 80 patients diagnosed with CHB between 2010 and 2018. Liver Biopsy was performed in each patients. Clinical, biochemical, and histological characteristics were examined. Patients with alcohol intake were excluded. Pathological data that were collected from biopsy reports included presence of steatosis (>5% of hepatocytes), presence of fibrosis according to Metavir staging, steatosis type and area.

Results: Thirty-eight men (48%) and 42 women (52%) were enrolled. The average age was 49 years. Most of patients (80%) was infected by mutant virus B, common type in Tunisia. the average level of viral DNA was 10881 IU/ml. 57% of patients had Metavir score >=F2 and 25% were cirrhotic. HS was present in 18% of patients (N=15). Their mean age was 47 years. 58% of patients with SH had Metavir score >=F2 but none was cirrhotic. Diffuse steatosis was found in 25% of cases. Our data showed that HS was not associated with age, sex, HBeAg, viral load, amount of fibrosis, transaminase levels, or alkaline phosphatase. Conversely, HS was significantly associated with type 2 diabetes (P<0.001), hypercholesterolemia (P=0.01) and body mass index BMI (P=0.02).

Conclusion: Concomitant hepatic steatosis and hepatitis B is relatively common in daily practice, although this association remains less frequent than observed in chronic hepatitis C. In our study overall HS prevalence was 18%. HS was significantly associated with metabolic factors, such as obesity, dyslipidemia and does not seem to influence the progression of liver fibrosis.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.